Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

LSD study reveals how tiny doses alter perception and choices

NCT ID NCT05976698

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how low doses of LSD change the way healthy adults make decisions based on what they see. Thirty participants completed computer tasks that tested their ability to predict and respond to visual patterns. The goal was to understand how LSD influences brain signals involved in learning and perception.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Feb 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willingness to adhere to the study protocol and sign the consent form * ≥ 18 and ≤ 65 years of age at Screening * Body mass index 18-29 * Fluent understanding of German * Normal or corrected-to-normal vision * Willingness to not operate a traffic vehicle or heavy machinery 24 hours after substance administration * Willingness to refrain from taking illicit psychoactive substances, including cannabis, for the duration of the study * Willingness to not consume more than one alcoholic standard drink the night before the study sessions and not consume alcohol for 24 h after each study session * Willingness to abstain from xanthine-based liquids from the evenings prior to the study sessions and during the sessions * Willingness to use effective birth-control throughout the study duration * Adequate task performance in the decision-making tasks during a practice session in the screening visit Exclusion Criteria: * Recent (\<30 days) or current participation in another clinical trial * Women that are pregnant, nursing, or planning to become pregnant during the study period * Current use of contraindicated/psychoactive medications or illicit drugs * Lifetime use of classical psychedelics more than 20 times, or any time within the previous two months * Consumption of \>5 cigarettes per day or \>20 alcoholic standard drinks per week * Severe chronic or acute medical condition * Hypertension (\>140/90 mmHg) or hypotension (\<85mmHg systolic) * Current or lifetime major mental health disorder * Personal or family (first-degree) history of a primary psychotic disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LSD reaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Psychiatric Clinics Basel

    Basel, 4002, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.